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Background
Worldwide, chronic infection with HBV and HDV occurs
in more than 10 million people with higher rates of devel-
oping cirrhosis, hepatic decompensation and hepatocellu-
lar carcinoma. Peginterferon (pegIFN) for 48 weeks is one
of the current therapies, with poor response rates;
prolonging therapy beyond 12 months might be of benefit
for the patients.
In order to assess the response to a prolonged pegIFN
therapy, we present 2 patients with chronic B/D coinfec-
tion, treated with pegIFN alpha 2a, 180 mcg weekly for
96 weeks and monitored, at least, every three months with
a complete medical evaluation.
Case report
Patient 1: Female age 30, diagnosed at age 19 with chronic
B/D coinfection; treated the first year with oral azathiopr-
ine for 12 weeks, then one week every three months; the
second year she started interferon alpha 2a for 48 weeks,
achieving biochemical and virologic response. At age 23,
she became pregnant, gave birth to a healthy baby girl
with no viral infection; after pregnancy, she had an ALT
10 times the upper normal limit, HBV-DNA 1,000,000 IU/
mL. For two years, she received support therapy: urso-
deoxycholic acid, vitamins, silymarin until we decided to
start peginterferon alpha 2a 180 mcg weekly for 48 weeks.
Well tolerated, we obtained undetectable HBsAg, HBV-
DNA and HDV-RNA in the serum and normal ALT. For
a sustained response, we decided to continue this treat-
ment for another 48 weeks. Until present she maintained
undetectable HBsAg, HBV-DNA and HDV-RNA; anti
HBs < 2.00 (limits 2-10 IU/L), anti-HBe: 0.012 COI
(reactive).
Patient 2: Male, 40 years old, diagnosed at age 36 with
chronic B/D coinfection; we started standard peginterferon
alpha 2a therapy for 48 weeks; with a major side-effect:
Hashimoto thyroiditis in month 3, successfully resolved.
We continued the treatment, then – also based on a
second-opinion from a French hospital – we indicated
another 48 weeks of treatment that resulted in sustained
biochemical and virologic response with viral eradication,
until present.
Conclusion
A long-term peginterferon therapy could be a chance for
cure in patients coinfected with HBV/HDV, with perma-
nent and rigorous monitoring and medical evaluation.
This approach needs further studies, for the benefit of
patients, considering the higher rates of mortality among
them.
Authors’ details
1Emergency Clinical County Hospital Craiova, Romania. 2University of
Medicine and Pharmacy Craiova, Romania. 3Clinical Hospital Filantropia
Craiova, Romania. 4Clinical Hospital Calafat, Romania. 5Medical Center SAMA,
Craiova, Romania.
Published: 15 October 2014
doi:10.1186/1471-2334-14-S7-P13
Cite this article as: Iliescu et al.: Chances for cure in chronic HBV/HDV
coinfection. BMC Infectious Diseases 2014 14(Suppl 7):P13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
* Correspondence: gabi_iliescu2002@yahoo.com
1Emergency Clinical County Hospital Craiova, Romania
Full list of author information is available at the end of the article
Iliescu et al. BMC Infectious Diseases 2014, 14(Suppl 7):P13
http://www.biomedcentral.com/1471-2334/14/S7/P13
© 2014 Iliescu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
